eosinophilic granulomatosis with polyangiitis; progressive weakness; This literature-non-study case was reported in a literature article and describes the occurrence of EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (eosinophilic granulomatosis with polyangiitis) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.      No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (eosinophilic granulomatosis with polyangiitis) (seriousness criterion medically significant) and ASTHENIA (progressive weakness). At the time of the report, EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (eosinophilic granulomatosis with polyangiitis) and ASTHENIA (progressive weakness) was resolving. Related    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Antineutrophil cytoplasmic antibody: elevated (High) Elevated anti-myeloperoxidase antibodies.. On an unknown date, Biopsy: abnormal (abnormal) Nerve and muscle biopsies showed focal vasculitis with infiltration by eosinophils..     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (eosinophilic granulomatosis with polyangiitis) and ASTHENIA (progressive weakness) to be related.    The patient presented with progressive weakness and paresthesia in the upper and lower extremities. Patient was found to have peripheral eosinophilia. The patient was started on steroids and a steroid-sparing agent shortly after that and had marked improvement of the symptoms. Company comment: This case concerns a 79-year-old female patient with no medical history reported, who experienced the unexpected serious (medically significant according to authority report), event of eosinophilic granulomatosis with polyangiitis, after the mRNA-1273 vaccine. The event occurred on an unknown date after the second dose of mRNA-1273 vaccine. Patient presented with progressive weakness and paresthesia in the upper and lower extremities. Labs showed peripheral eosinophilia and anti-myeloperoxidase antibodies. Nerve and muscle biopsies showed focal vasculitis with infiltration by eosinophils. The patient was treated with steroids and a steroid-sparing agent with marked improvement of the symptoms. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This case concerns a 79-year-old female patient with no medical history reported, who experienced the unexpected serious (medically significant according to authority report), event of eosinophilic granulomatosis with polyangiitis, after the mRNA-1273 vaccine. The event occurred on an unknown date after the second dose of mRNA-1273 vaccine. Patient presented with progressive weakness and paresthesia in the upper and lower extremities. Labs showed peripheral eosinophilia and anti-myeloperoxidase antibodies. Nerve and muscle biopsies showed focal vasculitis with infiltration by eosinophils. The patient was treated with steroids and a steroid-sparing agent with marked improvement of the symptoms. The benefit-risk relationship of mRNA-1273 is not affected by this report.